Pacific Biosciences Reports Q3 2026 Revenue of $40.6 Million, EPS of -$0. ...

SPRQ-Nx Adoption Expands Across Revio Installed Base While GAAP EPS of -$0.12 Beats Consensus of -$0.15 Related Stocks: PACB ,

Read original article